Health Tech Startups - How to Make It Work Globally?
Presented by SGInnovate
Healthcare technologies are essential in the prevention, diagnosis and treatment of illnesses and diseases. However, for new medtech and digital health innovations to break into the global stage is a complex and challenging endeavour. Join us in a panel discussion with leaders in the areas of health and life sciences as they tackle issues such as applying breakthrough technologies in addressing key health concerns in different parts of the world as well as what it takes for startups to gain a global foothold with their innovative and unique services.
Date : 2 October 2018
Time : 5:30 pm – 7:30pm
Venue : BASH, Level 3, Block 79 Ayer Rajah Crescent, Singapore 139955
5:30 pm – 6:00 pm: Registration
6:00 pm – 7:00 pm: Health Tech Startups - How to Make It Work Globally?
7:00 pm – 7:30 pm: Q&A and Networking Session
- Francois Cadiou, Founder & CEO, Healint
- Jeff Weisel, Director, Life Sciences & Healthcare, EY
- Hsien-Hsien Lei, Vice President Medical and Scientific Affairs APAC, Medtronic
- Joseph Mocanu, Managing Partner, Verge HealthTech Fund
Moderator: Will Greene, Healthcare Journalist & Strategy Consultant, Tigermine
Francois Cadiou, Founder & CEO, Healint
Francois Cadiou is the CEO and Founder of Healint, a health tech company that helps the one billion people who suffer from migraine and other neurological conditions. Healint is the developer of the world's largest migraine tracking and research platform, Migraine Buddy.
Before founding Healint in 2013, Cadiou was a senior technology and operations executive for the global biopharmaceutical giant Sanofi. His roles encompassed the development of key strategies and programs to improve the efficiency of drug development and of clinical trials for operations in Japan and in Europe. Cadiou later consulted for several international medtech firms and innovative technology start-up companies.
His inspiration for Healint arose out of a medical emergency when his father suffered a sudden stroke. Cadiou and his team realized there were numerous uses for technology that would allow people to monitor behavior, stress and other factors that could potentially predict the onset of a medical episode. This could be for stroke or a complex condition like migraine.
In 2014, Cadiou collaborated with top scientists and researchers and launched Migraine Buddy, which is now the top migraine tracking platform in the world with more than one million users. People use the Migraine Buddy app to track and record their migraine symptoms and condition. The patient reported outcomes generated via the platform helps patients understand their condition, and get the best possible diagnosis and treatment, and insights for research and clinical trials.
Born and raised in France, Cadiou has always been a natural problem solver and computer enthusiast. Time spent in the health care clinic where his mother worked inspired an interest in health care and the potential to find efficient solutions through technology to major health care challenges.
Cadiou received his MBA from Insead and a Master’s Degree in Science from ESSCA in Angers, France, and currently resides in Singapore with his wife and daughter.
Jeff Weisel, Director, Life Sciences & Healthcare, EY
Jeff Weisel has more than 25 years’ experience working with leading organizations across Asia-Pacific and the US on issues of strategic change and growth, with the last 20 years focused in the life sciences and healthcare sector. He is currently regional director of Life Sciences and Healthcare for EY focusing on M&A and corporate strategy. Before joining EY, Jeff ran a boutique advisory firm focused on capitalization and commercialization of healthtech, medtech and biotech start-ups from Southeast Asia, Australia and the US. He has been living and working in Asia since 1994.
Previously, Jeff was the Market Access & Policy Director for Asia, Australia, Africa, Middle East for Abbott where he developed and led the company’s engagement with governments, payers and other stakeholders. Before Abbott, he launched new businesses in patient care for Zuellig Pharma, the largest provider of services to the healthcare industry in Asia. From 2004 to 2008, Jeff led Novartis in major growth initiatives across Asia–Pacific in business development and licensing, key account management (KAM), market access and strategic planning.
Prior to joining Novartis, Jeff spent seven years with IBM and PwC Consulting, where he led the life sciences practice in Asia working with global and local market leaders, start-up companies and government organizations in pharmaceuticals, biotech, vaccines, diagnostics, medical devices, healthcare services and health insurance. Before PwC, Jeff advised multinational clients on regional market strategy with the Economist Intelligence Unit (EIU) and spent five years before that as a consultant on trade, regulatory and competitiveness issues in Washington, DC.
Jeff has served the American Chamber of Commerce in Singapore as a Board Governor and as Chair of the Healthcare Committee. He is also currently a Lecturer at ESSEC Business School’s Institute of Health Economics and Management.
He holds an M.A in Asian Studies and Economics from George Washington University and a B.A. in Political Science from Boston University.
Hsien-Hsien Lei, Vice President Medical and Scientific Affairs APAC, Medtronic
Dr. Hsien-Hsien Lei is Medtronic Vice President of Medical and Scientific Affairs, Asia Pacific.
Hsien has been an active member of AmCham Singapore since 2010 and became Healthcare Committee co-chair in 2013. She believes strongly in the Chamber’s mission to be the voice of American business in Singapore and the region by creating value for our members through advocacy, business insights, and connections. As Governor, Hsien would also make significant contributions to promoting diversity and inclusion by encouraging member companies to ensure that employees and business partners represent diverse viewpoints, feel valued and respected, and have access to the same opportunities at all levels.
Hsien has a PhD in Epidemiology from The Johns Hopkins University Bloomberg School of Public Health and a BA (with honors) in Human Biology from Stanford University. Hsien is also Vice Chair of the Asia Pacific Medical Technology Association (APACMed) medical and clinical affairs committee.
Joseph Mocanu, Managing Partner, Verge HealthTech Fund
Joseph Mocanu, Managing Partner, Verge HealthTech Fund
Joseph was previously Practice Head of Life Sciences and Digital Health, Asia-Pacific at Oliver Wyman.
Seasoned entrepreneur, strategist, scientist and angel investor, Joseph brings a hands-on end-to-end experience in the start-up journey, from research and commercialisation to investment and corporate scale-up. He has 19 scientific publications, 3 patents, and has made personal investments in 10+ healthcare technology companies.
Presently, Joseph is the founder and Managing Partner of Verge Capital Management currently raising its inaugural HealthTech Fund focusing on early stage healthcare technology companies. Prior to this, Joseph led life sciences and digital health across Asia for Oliver Wyman, a global management consultancy, where he focused on business model innovation, expanding access, consumer health, and investment strategies.
Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.
Will Greene, Healthcare Journalist & Strategy Consultant, Tigermine
Will Greene is a writer and strategy consultant focused on Asia's emerging R&D ecosystems, particularly in healthcare and the learning sciences. He currently runs Tigermine, a consultancy that helps science and technology leaders succeed in Asia.
Since 2010, he has worked with many of the region's top pharma/biotech and medtech firms, as well as innovative startups, trade associations, NGOs, universities, and research institutes. He also writes and speaks regularly about science and technology trends in Asia. He has published over 25 major media stories about healthcare innovation trends across the region, with bylines in Forbes, Techonomy, TechCrunch, The Diplomat, and other leading media outlets. He holds a B.A. in Political Science from Amherst College.
Topics: MedTech / HealthTech / BioTech
You may also like the following:
Real Successes and Applications of Digital Health
With levels of investments that have never been seen before (billions of dollars and counting), Digital Health is now moving faster than ever and every player in the industry needs to include it in their corporate strategies – from pharma companies to insurers, even brick and mortar hospital chains. However, the maturity level of corporates varies greatly, which dramatically impacts the success of the digitisation process in these organisations. During this fireside chat, industry veterans François Cadiou and Julien de Salaberry will share about the latest successes observed in Digital Health and how the stakeholders involved, from the corporates to the startups, manage to make it a success.Topics:
Corporate – Startup Collaborations in MedTech
Today, Singapore hosts more than 200 MedTech SMEs and startups, and over 60 multinational medtech firms that undertake activities from regional headquarters and manufacturing to research and development. These companies continue to provide tangible benefits for Singapore's research, innovation and enterprise and healthcare systems, and well position Singapore to serve the larger Asian marketplace.Topics:
Rising Stars in HealthTech: Data and Artificial Intelligence
SGInnovate, General Assembly and Galen Growth Asia are teaming up for a series of events with some of the most inspiring Southeast Asian healthtech founders and leaders. In a candid discussion, they will share their stories and insights on:Topics:
Artificial intelligence is already a part of our everyday lives, but for it to truly make a difference it needs to understand human emotions, says Live with AI founder Pierre Robinet.
This article is written by Pierre Robinet, who is a senior consulting partner at Ogilvy Consulting and founder of Live With AI, an independent think tank based in Singapore.